Profile data is unavailable for this security.
About the company
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
- Revenue in USD (TTM)191.72m
- Net income in USD-31.56m
- Incorporated1996
- Employees288.00
- LocationCerus Corp1220 Concord AvenueCONCORD 94520United StatesUSA
- Phone+1 (925) 288-6000
- Fax+1 (925) 288-6001
- Websitehttps://www.cerus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | 20.04m | -126.07m | 301.37m | 145.00 | -- | 1.17 | -- | 15.04 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Solid Biosciences Inc | 0.00 | -90.25m | 303.20m | 88.00 | -- | 1.42 | -- | -- | -3.94 | -3.94 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.74 | -49.99 | -40.68 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0075 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -163.66m | 304.05m | 74.00 | -- | 0.6028 | -- | -- | -1.96 | -1.96 | 0.00 | 5.99 | 0.00 | -- | -- | 0.00 | -27.48 | -5.90 | -28.78 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| ADC Therapeutics SA | 68.62m | -227.23m | 317.42m | 273.00 | -- | -- | -- | 4.63 | -2.77 | -2.77 | 0.8368 | -2.35 | 0.1769 | 0.2683 | 2.91 | 251,351.60 | -56.99 | -48.41 | -69.99 | -55.63 | 93.30 | -- | -322.09 | -308.62 | 4.35 | -4.14 | 1.85 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Anavex Life Sciences Corp | 0.00 | -40.59m | 319.10m | 40.00 | -- | 2.34 | -- | -- | -0.4962 | -0.4962 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -26.73 | -40.04 | -28.98 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 319.70m | 275.00 | -- | 0.5854 | -- | 1.15 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 320.68m | 163.00 | -- | 1.29 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Cerus Corp | 191.72m | -31.56m | 321.71m | 288.00 | -- | 6.51 | -- | 1.68 | -0.1742 | -0.1742 | 1.06 | 0.2671 | 0.9623 | 1.92 | 8.03 | 665,680.60 | -15.91 | -25.99 | -24.20 | -40.62 | 61.73 | 61.90 | -16.53 | -35.81 | 1.72 | -2.16 | 0.6287 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 323.32m | 1.60k | -- | 0.487 | -- | 0.2728 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Alto Neuroscience Inc | 0.00 | -42.44m | 323.41m | 67.00 | -- | 1.67 | -- | -- | -1.90 | -1.90 | 0.00 | 7.18 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | -31.02 | -- | -- | -- |
| Agenus Inc | 161.42m | -239.61m | 324.65m | 389.00 | -- | -- | -- | 2.01 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Xeris Biopharma Holdings Inc | 171.36m | -64.40m | 326.16m | 377.00 | -- | -- | -- | 1.90 | -0.4648 | -0.4648 | 1.24 | -0.0619 | 0.5209 | 0.838 | 5.02 | 454,525.20 | -19.58 | -43.60 | -25.58 | -56.57 | 82.90 | 78.23 | -37.58 | -143.08 | 1.81 | -2.04 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| OraSure Technologies, Inc. | 304.64m | 22.85m | 326.90m | 638.00 | 14.54 | 0.7669 | 7.63 | 1.07 | 0.304 | 0.304 | 4.11 | 5.76 | 0.6573 | 2.77 | 4.31 | 477,493.70 | 4.93 | 0.7238 | 5.42 | 0.8212 | 45.26 | 46.94 | 7.50 | 1.13 | 10.49 | -- | 0.0017 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Organogenesis Holdings Inc | 435.47m | 5.82m | 330.77m | 862.00 | 57.38 | 1.18 | 15.58 | 0.7596 | 0.0435 | 0.0435 | 3.28 | 2.11 | 0.9628 | 4.08 | 4.63 | 505,190.30 | 1.29 | 5.46 | 1.56 | 6.90 | 75.07 | 74.94 | 1.34 | 4.81 | 2.41 | 8.78 | 0.1955 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -79.79m | 335.83m | 54.00 | -- | 3.01 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 344.45m | 100.00 | -- | 228.42 | -- | 38.65 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
Data as of Jun 14 2024. Currency figures normalised to Cerus Corp's reporting currency: US Dollar USD
54.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Mar 2024 | 21.55m | 11.65% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 19.48m | 10.54% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 12.04m | 6.51% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.63m | 5.21% |
| PRIMECAP Management Co.as of 31 Mar 2024 | 8.58m | 4.64% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2024 | 7.75m | 4.19% |
| Senvest Management LLCas of 31 Mar 2024 | 7.33m | 3.96% |
| Wasatch Advisors LPas of 31 Mar 2024 | 6.28m | 3.40% |
| Geode Capital Management LLCas of 31 Mar 2024 | 4.16m | 2.25% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.67m | 1.99% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
